ZIM Laboratories gets marketing authorization for Rizatriptan Benzoate Orally Disintegrating Films

21 Jul 2025 Evaluate

ZIM Laboratories has received Marketing Authorization (MA) from Therapeutic Goods Administration (TGA), Australia for its Central Nervous System (CNS) product ‘Rizatriptan Benzoate Orally Disintegrating Films’ through its Australian Subsidiary, ZIMTAS.

This approval marks ZIM’s first Marketing Authorization in Australia and represents an important milestone in the Company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies.

Rizatriptan, a selective 5-HT?B/?D receptor agonist, is indicated for the acute treatment of migraine attacks, with or without aura, in adults. The orally disintegrating film (ODF) formulation developed using ZIM’s proprietary technology platform offers a patient-friendly alternative that enables rapid onset of action without the need for water, making it especially convenient for patients experiencing nausea or vomiting during migraine episodes.

This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience.

ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.

Zim Laboratories Share Price

70.68 -0.47 (-0.66%)
05-Dec-2025 14:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.50
Dr. Reddys Lab 1275.55
Cipla 1525.60
Zydus Lifesciences 933.80
Lupin 2101.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×